2027 Medicare Updates: What Independent IVIG Providers Should Know
For independent infusion providers preparing for 2027, an important distinction deserves attention: Medicare policies affecting a drug and payment for administering it operate separately.
That distinction is particularly relevant for practices with a substantial IVIG business. CMS has excluded plasma-derived products from its new international drug pricing model, while separate Medicare Physician Fee Schedule updates still warrant a review of administration reimbursement.
Plasma-Derived Products Are Excluded From GLOBE
CMS’s Global Benchmark for Efficient Drug Pricing, or GLOBE, model uses international pricing information to calculate manufacturer rebates for certain Medicare Part B drugs. The model launches January 1, 2027.
Under the final rule, plasma-derived products, including IVIG, are excluded. That exclusion applies specifically to GLOBE; it does not exempt a practice’s infusion services from other Medicare payment policies.
Administration Payments Require a Separate Review
Medicare payment for an infusion includes distinct components for the therapy and the services involved in administering it. Understanding one component does not establish the financial outlook for the other.
For 2027, CMS reports an approximately 2.31% decrease in the standard Physician Fee Schedule conversion factor for clinicians who are not qualifying Alternative Payment Model participants, from $33.40 to $32.63. The decrease reflects, in part, the expiration of a temporary payment increase provided for 2026.
The conversion factor translates relative value units into payment amounts. Its decrease does not mean every administration code will decline by the same percentage, because updated code valuations and geographic adjustments also affect payment.
What Could This Mean for Your Practice?
Consider an administration service with a hypothetical Medicare allowed amount of $100 in 2026. Holding its relative value units and geographic adjustments constant, an approximately 2.31% decrease in the conversion factor would bring that amount to about $97.69 in 2027.
For a practice billing that service 100 times each month, the difference would total approximately $2,772 annually for that service alone.
This illustrates the conversion factor’s effect, rather than a published rate for a specific billing code. The amounts represent total allowed reimbursement, including beneficiary cost-sharing, before sequestration and other applicable adjustments.
For IVIG providers, the example demonstrates why exclusion from GLOBE does not eliminate the need to assess administration reimbursement.

“Behind every infusion is a team, a treatment space and the resources needed to care for that patient safely,” says Katie Ivy, President and COO of Infinity Infusion Solutions. “As reimbursement evolves, payment policies need to recognize what it takes to sustain care in independent practices.”
Preparing Your Practice for January
A focused reimbursement review can help turn policy updates into useful planning:
- Compare administration rates. Review 2026 and 2027 Medicare payment amounts for frequently billed codes, including applicable geographic adjustments.
- Estimate the financial impact. Apply those rates to expected Medicare service volume to understand the potential effect on revenue.
- Review the full economics of care. Evaluate drug acquisition costs and reimbursement alongside administration revenue and the costs of delivering treatment.
- Align your team. Have billing and practice leadership review the findings together and identify questions requiring clarification before January.
These steps can help practices assess their own exposure without assuming every infusion provider will experience the same result.
Go Beyond with IIS
Infinity Infusion Solutions is a specialized GPO and medical consultancy supporting ambulatory infusion centers (AICs) and independent providers. With more than 2,700 member infusion sites nationwide and over a decade of leadership in independent infusion care, we understand how reimbursement affects practice sustainability and patient access.
Our support goes beyond purchasing. We help members understand how acquisition costs and reimbursement work together to shape the financial health of their infusion business, with strategic guidance grounded in the realities of buy-and-bill.
As you prepare for 2027, Go Beyond reviewing payment changes. Work with a partner who can help you put them in context for your practice and take informed steps to strengthen your infusion business.
Go Beyond with IIS. Explore how we can support your practice.
